Logo

Drexel University

HHS, Cohen Foundation Award $1M to Lyme Disease Dx Research Projects

The funding is being provided to 10 groups through the LymeX Diagnostics Prize initiative, which was launched in late 2020 by theHHS- and Cohen Foundation-backed Lyme Innovation Accelerator.

Brain Cancer Coalition Plans Precision Medicine Study

The study will use NantHealth's GPS Cancer test to help treat adult and pediatric brain cancer patients.

Philly's University City Science Center Debuts $1.2M POC Fund for Academic Life-Sci Projects
Premium

In the first phase of the three-part pilot program, three projects will be chosen from 10 institutions in the Philadelphia region, Delaware, and New Jersey to receive one-year grants worth as much as $200,000 for proof-of-concept studies.

Short Reads: Mar 27, 2009
Premium

News in brief

Snippets: Mar 4, 2009
Premium

DNAPrint, Laboratory Corporation of America, Duke University, Lab21, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Diseases and Stroke, and more …
Breaking News
The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.